Skip to content

Dyspnea Neuroscience Education on Patients With Chronic Obstructive Pulmonary Disease

Dyspnea Neuroscience Education on Patients With Chronic Obstructive Pulmonary Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04987125
Enrollment
40
Registered
2021-08-03
Start date
2021-10-01
Completion date
2022-05-01
Last updated
2021-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyspnea

Keywords

Education, Neuroscience education

Brief summary

The principal aim of this study was to adapt pain neuroscience education to dyspnea, Dyspnea Neuroscience Education (DNE), and measure its effect on dyspnea perception, physica l activity level, disability, quality of life and ventilatory and functional capacity through a randomized controlled trial. The secondary objectives were to evaluate its feasibility and its effect on emotional state (anxiety and depression), medical atten dance, number of exacerbations and the willingness to exercise.

Interventions

BEHAVIORALDyspnea Neuroscience education

Patients will follow an online therapeutic education course about dyspnea. Education about the cognitive and emotional aspects of dyspnea processing, with the goal of changing maladaptive cognitions and behaviors. The course will be group-based (5 participants). The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour.

BEHAVIORALUsual care

General health advice, physiotherapy treatment. The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour.

Sponsors

Cardenal Herrera University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Diagnostic of COPD by a physician or pneumologist * Stage 1, 2 or 3 on the GOLD Classification * GOLD Stage and FEV1 assessed by a physician in the last three months * Access to a computer and internet

Exclusion criteria

* Cognitive impairment (MoCA-S score \< 21) * Depression disorder (PHQ-9 score ≥11) * Generalized Anxiety Disorder (GAD-7 score ≥10) * Instable comorbidities preventing physical activities * Had a surgery in the past three months * Had an exacerbation in the past three months * Currently quitting tobacco * Use of oxygenation

Design outcomes

Primary

MeasureTime frame
Change from Self-efficacy Scale for Physical Activity questionnaire at 4 and weeks and 6 monthsPreintervention, postintervention (4 weeks) and follow-up (6 months).
Change from Level of Physical Activity questionnaire at 4 and weeks and 6 monthsPreintervention, postintervention (4 weeks) and follow-up (6 months).
Change from Perception of Dyspnea questionnaire at 4 and weeks and 6 monthsPreintervention, postintervention (4 weeks) and follow-up (6 months).
Change from Activity-related intensity and unpleasantness of perceived dyspnea questionnaire at 4 and weeks and 6 monthsPreintervention, postintervention (4 weeks) and follow-up (6 months).
Change from disability questionnaire at 4 and weeks and 6 monthsPreintervention, postintervention (4 weeks) and follow-up (6 months).
Change from Quality of Life about respiratory disease questionnaire at 4 and weeks and 6 monthsPreintervention, postintervention (4 weeks) and follow-up (6 months).

Secondary

MeasureTime frame
Change from FEV1 physiological parameter at 4 and weeks and 6 monthsPreintervention, postintervention (4 weeks) and follow-up (6 months).
Change from Six Minute Walk Test (Sp02% Change) physiological parameter at 4 and weeks and 6 monthsPreintervention, postintervention (4 weeks) and follow-up (6 months).
Change from Forced vital capacity physiological parameter at 4 and weeks and 6 monthsPreintervention, postintervention (4 weeks) and follow-up (6 months).

Contacts

Primary ContactLuis Suso-Martí, PhD
luis.suso@gmail.com627819667

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026